Prevalence of multiple sclerosis and environmental factors in Kerman province, Iran

Neurology Asia

Volumn 18, Issue 4, 2013, Pages 385-389

  Ebrahimi, Hossein Ali ^a   Sedighi, Behnaz ^a  

^a KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; COPPER;

ADOLESCENT; ADULT; ARTICLE; COLD EXPOSURE; DISABILITY; DISEASE DURATION; DISEASE REGISTRY; ENVIRONMENTAL FACTOR; ENVIRONMENTAL TEMPERATURE; FEMALE; HUMAN; IRAN; KURTZKE DISABILITY STATUS SCALE; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MULTIPLE SCLEROSIS; NEUROLOGY; ONSET AGE; POPULATION RESEARCH; PRACTICE GUIDELINE; PREVALENCE; RATING SCALE; RURAL AREA; SEX RATIO; TREATMENT DURATION; UNIVERSITY HOSPITAL; YOUNG ADULT;

EID: 84891083549     PISSN: 18236138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000; 343:938-52.
2. Anderson DW, Ellenberg JH, Leventhal CM, Reingold SC, Rodriguez M, Silberberg DH. Revised estimate of the prevalence of multiple sclerosis in the United States. Ann Neurol 1992; 31:333-6.
3. Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R. How common are the "common" neurologic disorders? Neurology 2007; 68:326-37.
4. Alonso A, Hernan MA. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology 2008; 71:129-35.
5. Mayr WT, Pittock SJ, McClelland RL, Jorgensen NW, Noseworthy JH, Rodriguez M. Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985-2000. Neurology 2003; 61:1373-7.
6. Pugliatti M, Rosati G, Carton H, et al. The epidemiology of multiple sclerosis in Europe. Eur J Neurol 2006; 13:700-22.
7. Orton SM, Herrera BM, Yee IM, et al. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol 2006; 5:932-6.
8. Sahraian MA, Khorramnia S, Ebrahim MM, Moinfar Z, Lotfi J, Pakdaman H, Multiple sclerosis in Iran. Eur Neurol 2010; 64(6):331-6.
9. Saadatnia M, Etemadifar M, Maghzi AH. Multiple sclerosis in Isfahan, Iran. Int Rev Neurobiol 2007; 79:357-75.
10. Stüve O, Oksenberg J. Multiple sclerosis overview. Gene Reviews Seattle (WA): University of Washington, Seattle; 1993-2006 Jan 10 [updated 2010 May 11].
11. Hosking MP, Thomas E. The biology of persistent infection: Inflammation and demyelination following murine coronavirus infection of the central nervous system. Curr Immunol Rev 2009; 5(4):267-76.
12. Handel AE, Williamson AJ, Disanto G, Dobson R, Giovannoni G, Ramagopalan SV. Smoking and multiple sclerosis: an updated meta-analysis. PLoS One 2011;6(1): e16149. doi:10.1371/journal. pone.0016149
13. Conradi S, Malzahn U, Schröter F, et al. Environmental factors in early childhood are associated with multiple sclerosis: a case-control study. BMC Neurol 2011; 11:123.
14. Sloka JS, Pryse-Phillips WE, Stefanelli M. The relation of ultraviolet radiation and multiple sclerosis in Newfoundland. Can J Neurol Sci 2008; 35(1):69-74.
15. Handel AE, Jarvis L, McLaughlin R, Fries A, Ebers GC, Ramagopalan SV. The epidemiology of multiple sclerosis in Scotland: inferences from hospital admissions. PLoS One 2011; 6(1):e14606. doi:10.1371/journal.pone.0014606
16. Munger KL, Levin LL, Hollis BW, et al. Serum 25-hydroxyvitamin 0 levels and risk of multiple sclerosis. JAMA 2006; 296:2832-8.
17. Johnson S. The possible role of gradual accumulation of copper, cadmium, lead and iron, and gradual depletion of zinc, magnesium, selenium, vitamins B2, B6, D and E and essential fatty acids in multiple sclerosis. Med Hypotheses 2000; 55(3):239-41.
18. Habib CA, Zheng WL, Haacke EM, Webb S, Nichol H. Visualizing iron deposition in multiple sclerosis cadaver. Brains Neurol Sci 2001; 22(2):117-39.
19. www.tebian.net/Iran/province/Kermam
20. htpp://geography. kermanedu. ir/abutk3. htm
21. htpp://www.amar.org.ir/linkclick.aspx?
22. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis. Neurology 1996; 46:907-9.
23. R Palm and G Hallmans. Zinc and copper in multiple sclerosis. J Neurol Neurosurg Psychiatry 1982; 45(8):691-98.
24. Rodriguez M. Advances in multiple sclerosis and experimental demyelinating diseases. Springer publishing 2008: 3
25. Sadovnick AD, Scheifele DW. School-based hepatitis B vaccination program and adolescent multiple sclerosis. Lancet 2000; 355:549-50.
26. Orton SM, Wald L, Confavraux C, et al. Association of UV radiation with multiple sclerosis prevalence and sex ratio in France. Neurology 2011; 75(5):425-31.
27. Orton SM, Herrera BM, Yee IM, et al. Sex ratio of multiple sclerosis in Canada. Lancet Neurol 2006; 5(11):932-6.
28. Tremlett H, Paty D, Devonshire V. Disability progression in multiple sclerosis is slower than previously reported. Neurology 2006; 66(2):172-7.
29. Simon KC, van der Mei IA, Munger KL, et al. Combined effects of smoking, anti-EBNA antibodies, and HLA-DRB1*1501 on multiple sclerosis risk. Neurology 2010; 74:1365-71.
30. Healy BC, Ali EN, Guttmann CR, et al. Smoking and disease progression in multiple sclerosis. Arch Neurol 2009; 66(7):858-64.
31. Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain 2006; 129:606-16.
32. Pachner AR, Steiner I. The multiple sclerosis severity score (MSSS) predicts disease severity over time. J Neurol Sc 2009; 278(1):66-70.
33. Jelinek G. Overcoming multiple sclerosis: An evidencebased guide to recovery. Allen & Unwin, 2010.
34. Brown MG, Kirby S, Skedgel C, et al. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS? Neurology 2007; 69(15):1498-507.
35. Shaw CM, Alvord EC. Multiple sclerosis beginning in infancy. J Child Neurol 1987; 2:252-6.
36. Ghezzi A, Deplano V, Faroni J, et al. Multiple sclerosis in childhood: clinical features of 149 cases. Mult Scler 1997; 3:43-6.
37. Goodin DS. The causal cascade to multiple sclerosis: A model for MS pathogenesis PLoS ONE 2009; 4(2):e4565